RogCon, Inc.

RogCon, Inc., also known as "The SCN2A Company," is a biotechnology firm founded in 2015, headquartered in the United States, and specializing in drug research, discovery, and development for select ion channelopathies. With a primary focus on SCN2A, the company operates within the biotechnology and health care sectors. Although there is no publicly available information regarding the last investment round and the associated investors, RogCon, Inc.'s dedicated focus on SCN2A and its activities in drug development position it as a promising player in the biotechnology and health care industries.